Two recently approved therapies for advanced prostate cancer directly target the androgen receptor signaling pathway: abiraterone by preventing androgen synthesis, and enzalutamide by blocking interaction of the receptor with its ligands. This evidence concerns the gene AR and Familial prostate cancer.